Nabi Biopharmaceuticals - Product Pipeline Review - 2012


#138375

48pages

Global Markets Direct

$ 1500

In Stock


Nabi Biopharmaceuticals Product Pipeline Review 2012

Global Market Directs pharmaceuticals report, Nabi Biopharmaceuticals Product Pipeline Review 2012 provides data on the Nabi Biopharmaceuticalss research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Nabi Biopharmaceuticalss corporate website, SEC filings, investor presentations and featured press releases, both from Nabi Biopharmaceuticals and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

  • Nabi Biopharmaceuticals Brief Nabi Biopharmaceuticals overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Nabi Biopharmaceuticals human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Nabi Biopharmaceuticals with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the Nabi Biopharmaceuticalss pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate Nabi Biopharmaceuticalss strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of Nabi Biopharmaceuticals in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the Nabi Biopharmaceuticalss R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with Nabi Biopharmaceuticals. 
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of Nabi Biopharmaceuticals and identify potential opportunities in those areas.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Nabi Biopharmaceuticals Snapshot 5
Nabi Biopharmaceuticals Overview 5
Key Information 5
Key Facts 5
Nabi Biopharmaceuticals Research and Development Overview 6
Key Therapeutic Areas 6
Nabi Biopharmaceuticals Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products Monotherapy 9
Nabi Biopharmaceuticals Pipeline Products Glance 10
Nabi Biopharmaceuticals Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Nabi Biopharmaceuticals Early Stage Pipeline Products 11
Discovery Products/Combination Treatment Modalities 11
Nabi Biopharmaceuticals Drug Profiles 12
EnteroVAX 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
NicVAX 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
RENs 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Nabi Biopharmaceuticals Pipeline Analysis 16
Nabi Biopharmaceuticals Pipeline Products by Therapeutic Class 16
Nabi Biopharmaceuticals Pipeline Products by Route of Administration 17
Nabi Biopharmaceuticals Pipeline Products By Mechanism of Action 18
Nabi Biopharmaceuticals Recent Pipeline Updates 19
Nabi Biopharmaceuticals - Dormant Projects 20
Nabi Biopharmaceuticals - Discontinued Pipeline Products 21
Discontinued Pipeline Product Profiles 21
StaphVAX 21
Nabi Biopharmaceuticals Company Statement 22
Nabi Biopharmaceuticals Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Nabi Biopharmaceuticals, Recent Developments 25
Nabi Biopharmaceuticals- Press Release 25
Sep 29, 2009: Nabi Biopharmaceuticals Receives Grant Supporting Further NicVAX Development 25
Jun 03, 2009: Nabi Biopharmaceuticals Receives Scientific Advice On NicVAX From The European Medicines Agency 25
Financial Deals Landscape 27
Nabi Biopharmaceuticals, Deals Summary 27
Nabi Biopharmaceuticals, Pharmaceuticals & Healthcare, Deal Details 28
Partnerships 28
Nabi BioPharma Enters Into Research Agreement With USU And The Henry M. Jackson Foundation 28
Nabi BioPharma Enters Into Collaboration With National Institute Of Allergy And Infectious Diseases 30
Nabi BioPharma Enters Into Co-Development Agreement With Kedrion 32
Merger 34
Biota To Merge With Nabi Biopharma 34
Licensing Agreements 36
Nabi BioPharma Enters Into License Agreement With GlaxoSmithKline 36
Nabi BioPharma Enters Into Agreement With ProMetic Life Sciences 38
Asset Transactions 39
GlaxoSmithKline Acquires PentaStaph And Related Assets From Nabi BioPharma 39
Biotest Acquires Biologics Business Unit From Nabi BioPharma 41
Bioniche Teoranta Acquires Aloprim From Nabi BioPharma 43
Fresenius Medical Care Acquires Rights Of PhosLo From Nabi BioPharma 45

Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

Nabi Biopharmaceuticals, Key Information 5
Nabi Biopharmaceuticals, Key Facts 5
Nabi Biopharmaceuticals Pipeline by Indication, 2012 7
Nabi Biopharmaceuticals Pipeline by Stage of Development, 2012 8
Nabi Biopharmaceuticals Monotherapy Products in Pipeline, 2012 9
Nabi Biopharmaceuticals Phase III, 2012 10
Nabi Biopharmaceuticals Discovery, 2012 11
Nabi Biopharmaceuticals Pipeline By Therapeutic Class, 2012 16
Nabi Biopharmaceuticals Pipeline By Route of Administration, 2012 17
Nabi Biopharmaceuticals Pipeline Products By Mechanism of Action, 2012 18
Nabi Biopharmaceuticals Recent Pipeline Updates, 2012 19
Nabi Biopharmaceuticals - Dormant Developmental Projects,2012 20
Nabi Biopharmaceuticals - Discontinued Pipeline Products, 2012 21
Nabi Biopharmaceuticals, Other Locations 24
Nabi Biopharmaceuticals, Deals Summary 27
Nabi BioPharma Enters Into Research Agreement With USU And The Henry M. Jackson Foundation 28
Nabi BioPharma Enters Into Collaboration With National Institute Of Allergy And Infectious Diseases 30
Nabi BioPharma Enters Into Co-Development Agreement With Kedrion 32
Biota To Merge With Nabi Biopharma 34
Nabi BioPharma Enters Into License Agreement With GlaxoSmithKline 36
Nabi BioPharma Enters Into Agreement With ProMetic Life Sciences 38
GlaxoSmithKline Acquires PentaStaph And Related Assets From Nabi BioPharma 39
Biotest Acquires Biologics Business Unit From Nabi BioPharma 41
Bioniche Teoranta Acquires Aloprim From Nabi BioPharma 43
Fresenius Medical Care Acquires Rights Of PhosLo From Nabi BioPharma 45
Nabi Biopharmaceuticals Pipeline by Indication, 2012 7
Nabi Biopharmaceuticals Pipeline by Stage of Development, 2012 8
Nabi Biopharmaceuticals Monotherapy Products in Pipeline, 2012 9
Nabi Biopharmaceuticals Pipeline By Therapeutic Class, 2012 16